Grandbrothers/iStock Editorial via Getty Images Regeneron ( NASDAQ: REGN ) and Sanofi ( NASDAQ: SNY ) announced Friday that the U.S. FDA approved a label expansion for its asthma therapy Dupixent (dupilumab) for certain patients with chronic obstructive pulmonary disease (COPD), a respiratory disorder.
With its latest approval, the inflammatory disease therapy, already.
